IMCR supply chain intelligence for Immunocore Holdings plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Immunocore Holdings plc (IMCR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GATES-FOUNDATION | GATES-FOUNDATION | 90% | Under the terms of the Company's agreement with the Gates Foundation, the Company is required to develop, manufacture and commercialize soluble TCR bispecific therapeutic candidates targeted to mutua… |
| MEDISON | MEDISON | 85% | Under the revised agreement, the Company received a non-refundable payment of $ 5.0 million in exchange for granting Medison exclusive distribution rights in South America. |
| MEDISON-PHARMA-LTD | MEDISON-PHARMA-LTD | 85% | of net revenue from sale of therapies relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks and returns, which are recognized … |
| IMMUNOCORE-HOLDINGS | IMMUNOCORE-HOLDINGS | 62% | ity to allot up to a maximum nominal value of £ 149,633 and shares as of March 31, 2026 and December 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of March 31… |
| IMMUNOCORE-IRELAND-LIMITED-IMMUNOCORE-GMBH | IMMUNOCORE-IRELAND-LIMITED-IMMUNOCORE-GMBH | 62% | ity to allot up to a maximum nominal value of £ 149,633 and shares as of March 31, 2026 and December 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of March 31… |
| IMMUNOCORE-LIMITED-IMMUNOCORE-LLC-IMMUNOCORE-COM | IMMUNOCORE-LIMITED-IMMUNOCORE-LLC-IMMUNOCORE-COM | 62% | ity to allot up to a maximum nominal value of £ 149,633 and shares as of March 31, 2026 and December 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of March 31… |
| IMMUNOCORE-NOMINEES-LIMITED | IMMUNOCORE-NOMINEES-LIMITED | 62% | ity to allot up to a maximum nominal value of £ 149,633 and shares as of March 31, 2026 and December 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of March 31… |
| U-S-BANK-TRUST-COMPANY | U-S-BANK-TRUST-COMPANY | 62% | 132,780 Provisions related to sales in the period 23,275 10,362 113 33,750 Credits and payments made ( 11,462 ) ( 10,359 ) ( 185 ) ( 22,006 ) As of March 31, 2026 $ 141,344 $ 2,685 $ 495 $ 144,524 De… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IMCR-DEBT | Debt stack $438.7M | 90% | Market cache reports total debt of $438.7M. |
| IMCR-DEBT-10233 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IMCR-OWNER-RTW-INVESTMENTS-LP | RTW INVESTMENTS, LP | 90% | 13F overlay lists RTW INVESTMENTS, LP as top holder; 145 tracked holders. |